Novo Nordisk will pay $300 million upfront to license a preclinical weekly oral GLP-1/GIP receptor agonist from China’s Hengrui Pharma. The licensed asset is designed for once-weekly dosing and is expected to enter Phase 1 development. Novo’s agreement also puts a larger value of up to $2.6 billion on the relationship if milestones are met, extending the Danish company’s push to broaden its obesity franchise with differentiated delivery and dosing convenience. The deal highlights how next-generation incretin products are shifting from only injectable efficacy to a wider set of competitive attributes—oral availability and reduced dosing frequency—that can reshape payer, adherence, and patient experience considerations. For Hengrui, the transaction is another proof point that non-sterile delivery formats can attract global partnerships even before clinical results are available, with Novo positioning the program as a pipeline reinvestment while it manages capacity and competitive pressure in GLP-1s.